Ctr Oakwater LLC — research payments reported

By program year

1 row

Year	Kind	Amount	Payments
2025	Research	$691,766	36

Breakdown

Who paid Research payments · program year 2025

Vertex Pharmaceuticals Incorporated $512,989 4 payments
Eli Lilly and Company $85,868 2 payments
Takeda Pharmaceuticals U.S.A., Inc. $27,709 20 payments
Amgen Inc. $23,500 1 payment
Calliditas Therapeutics US Inc. $21,800 5 payments
Hoffmann-La Roche Limited $19,899 4 payments

Studies the money was for Research payments · program year 2025

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) $226,080 1 payment
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $173,062 1 payment
A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease $81,108 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $55,254 1 payment
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy $32,740 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $30,614 1 payment
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition $27,709 20 payments
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis $23,500 1 payment
Nef-403 $21,800 5 payments
Double blind study to determine efficacy of ASO Factor B in IgAN $19,899 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.